Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal peritoneal metastases

被引:0
|
作者
Cashin, Peter Harald [1 ]
Asplund, Dan [2 ,6 ]
Lindskog, Elinor Bexe [2 ]
Ghanipour, Lana [1 ]
Syk, Ingvar [3 ]
Graf, Wilhelm [1 ]
Nilsson, Per J. [4 ,5 ]
Palmer, Gabriella Jansson [4 ,5 ]
机构
[1] Uppsala Univ Hosp, Uppsala, Sweden
[2] Sahlgrens Univ Hosp, Dept Surg, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Skanes Univ Hosp, Malmo, Sweden
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden
关键词
Colorectal cancer; Peritoneal metastases; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Relapse treatment; Systemic chemotherapy; SYSTEMIC CHEMOTHERAPY; CARCINOMATOSIS; MULTICENTER; PROGNOSIS; CANCERS;
D O I
10.1016/j.sopen.2024.05.018
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Secondary treatment of recurrent colorectal peritoneal metastases after previous cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly investigated. Objectives: To evaluate the overall survival outcome of secondary (repeat) CRS + HIPEC compared to palliative treatment in recurrent peritoneal disease. Methods: Patients with colorectal peritoneal metastases treated with an index CRS + HIPEC and subsequently having recurrent peritoneal disease were identified from the prospective Swedish national HIPEC registry. Patients were divided into interventional group (secondary CRS + HIPEC) or palliative group. Multivariable logistic regression, propensity-score matching, and survival outcomes were calculated. Results: Among 575 patients who underwent complete CRS between 2010 and 2021, 208 (36 %) were diagnosed with a subsequent recurrent peritoneal disease. Forty-two patients (20 %) were offered secondary CRS + HIPEC. Propensity-score matching of secondary interventional cases with palliative cases succeeded in 88 % (n = 37) in which female sex, lower peritoneal cancer index at index surgery, longer disease-free interval, and absence of extra-peritoneal metastases were identified as the most relevant matching covariates. Median OS from date of recurrence was 38 months (95%CI 30-58) in the interventional group and 19 months (95%CI: 15-24) in the palliative group (HR 0.35 95%CI: 0.20-0.63, p = 0.0004). Sensitivity analyses confirmed the results. As reference, the median OS from index CRS + HIPEC in the whole colorectal registry (n = 575) was 41 months (95%CI: 38-45). Conclusion: After matching for relevant factors, the hazard ratio for death was significantly reduced in patients who were offered a secondary CRS + HIPEC procedure for recurrent peritoneal disease. Selection bias is inherent, but survival outcomes were comparable to those achieved after the initial procedure.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [21] Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
    Dietz, Michelle V.
    Hannink, Gerjon
    Said, Ibrahim
    van der Zant, Femke A.
    van de Vlasakker, Vincent C. J.
    Brandt-Kerkhof, Alexandra R. M.
    Verhoef, Cornelis
    Bremers, Andreas J. A.
    de Wilt, Johannes H. W.
    Hemmer, Patrick H. J.
    de Hingh, Ignace H. J. T.
    de Reuver, Philip R.
    Madsen, Eva V. E.
    EJSO, 2024, 50 (06):
  • [22] Management of peritoneal surface metastases from colorectal cancer: Cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, pressurized intraperitoneal chemotherapy, and beyond
    Mangieri, Christopher W.
    Levine, Edward A.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience
    Narasimhan, Vignesh
    Britto, Maneka
    Toan Pham
    Warrier, Satish
    Naik, Arun
    Lynch, A. Craig
    Michael, Michael
    Tie, Jeanne
    Ramsay, Robert
    Heriot, Alexander
    DISEASES OF THE COLON & RECTUM, 2019, 62 (10) : 1195 - 1203
  • [24] Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Birgisson, Helgi
    Enblad, Malin
    Artursson, Sara
    Ghanipour, Lana
    Cashin, Peter
    Graf, Wilhelm
    EJSO, 2020, 46 (12): : 2283 - 2291
  • [25] Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of peritoneal metastasis
    Sokmen, Selman
    Bisgin, Tayfun
    Manoglu, Berke
    Altay, Canan
    Ellidokuz, Hulya
    TURKISH JOURNAL OF SURGERY, 2022, 39 (01) : 43 - 51
  • [26] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Peritoneal Metastases
    Ruff, Samantha M.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2025, 34 (02) : 241 - 251
  • [27] Pelvic exenteration combined with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for advanced primary or recurrent colorectal cancer with peritoneal metastases
    Brown, Kilian G. M.
    Ansari, Nabila
    Solomon, Michael J.
    Austin, Kirk K. S.
    Hamilton, Auerilius E. R.
    Young, Christopher J.
    COLORECTAL DISEASE, 2021, 23 (01) : 186 - 191
  • [28] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: Where do we stand?
    Witmer, Hunter D. D.
    Dhiman, Ankit
    Turaga, Kiran K.
    CANCER, 2023, 129 (04) : 495 - 502
  • [29] Does the primary tumour location affect the prognosis of patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
    Chen, Haipeng
    Zhou, Sicheng
    Bi, Jianjun
    Feng, Qiang
    Jiang, Zheng
    Xu, Jianping
    Pei, Wei
    Liang, Jianwei
    Zhou, Zhixiang
    Wang, Xishan
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [30] Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    van Eden, Wijntje J.
    Kok, Niels F.
    Jozwiak, Katarzyna
    Lahaye, Max L.
    Beets, Geerard L.
    van Leerdam, Monique E.
    Boot, Henk
    Aalbers, Arend G.
    DISEASES OF THE COLON & RECTUM, 2017, 60 (05) : 477 - 487